European Union - English - EMA (European Medicines Agency)

bluebird bio (netherlands) b.v. - autologous cd34+ cell enriched population that contains hematopoietic stem cells transduced with lentiglobin bb305 lentiviral vector encoding the beta-a-t87q-globin gene - beta-thalassemia - other hematological agents - zynteglo is indicated for the treatment of patients 12 years and older with transfusion-dependent β thalassaemia (tdt) who do not have a β0/β0 genotype, for whom haematopoietic stem cell (hsc) transplantation is appropriate but a human leukocyte antigen (hla)-matched related hsc donor is not available.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - deferasirox -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - deferasirox -

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - deferasirox, quantity: 125 mg - tablet, dispersible - excipient ingredients: microcrystalline cellulose; sodium lauryl sulfate; povidone; magnesium stearate; colloidal anhydrous silica; lactose monohydrate; crospovidone; croscarmellose sodium - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. deferasirox is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective.,deferasirox is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - deferasirox, quantity: 250 mg - tablet, dispersible - excipient ingredients: colloidal anhydrous silica; croscarmellose sodium; povidone; lactose monohydrate; sodium lauryl sulfate; microcrystalline cellulose; magnesium stearate; crospovidone - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. deferasirox is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective.,deferasirox is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - deferasirox, quantity: 500 mg - tablet, dispersible - excipient ingredients: crospovidone; croscarmellose sodium; lactose monohydrate; povidone; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; sodium lauryl sulfate - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. deferasirox is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective.,deferasirox is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.

Singapore - English - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - deferasirox - tablet, film coated - deferasirox 360.00mg

Singapore - English - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - deferasirox - tablet, film coated - deferasirox 90mg

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - deferasirox, quantity: 125 mg - tablet, dispersible - excipient ingredients: hyprolose; dibasic sodium phosphate; crospovidone; microcrystalline cellulose; colloidal anhydrous silica; hypromellose; sodium lauryl sulfate; hydrogenated castor oil; magnesium stearate - deferasirox is indicated in the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. it is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. ,deferasirox is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - deferasirox, quantity: 250 mg - tablet, dispersible - excipient ingredients: crospovidone; sodium lauryl sulfate; hydrogenated castor oil; hypromellose; microcrystalline cellulose; hyprolose; colloidal anhydrous silica; magnesium stearate; dibasic sodium phosphate - deferasirox is indicated in the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. it is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. ,deferasirox is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.